Milesblue42
2 weeks ago
NO Pump: Bucillamine + Molecular hydrogen = ????
DISCLAIMER: This post is not designed to try and pump this stock but merely a question. Could a combination of Bucillamine and Molecular hydrogen actually have real medical benefits? Benefits that could possibly significantly impact the share price? Or is this merely an elaborate time buying tactic that will amount to nothing at all?
https://www.globenewswire.com/news-release/2025/03/03/3035573/0/en/Revive-Therapeutics-Announces-LOI-to-Acquire-DiagnaMed-s-Molecular-Hydrogen-Program.html
Revive Therapeutics Announces LOI to Acquire DiagnaMed’s Molecular Hydrogen Program
March 03, 2025 08:00 ET | Source: Revive Therapeutics Ltd.
Share
TORONTO, March 03, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases, rare disorders, and medical countermeasures, is pleased to announce that it has entered into a non-binding letter of intent (the “LOI”), dated February 28, 2025, to acquire the full rights to DiagnaMed Holdings Corp.’s (CSE: DMED) (OTCQB: DGNMF) (“DiagnaMed”) intellectual property (the “Acquired Assets”) pertaining to molecular hydrogen as potential treatments for neurological and mental health disorders (the “Acquisition”).
Molecular hydrogen, a small molecule with antioxidant and anti-inflammatory properties, has shown early promise in preclinical studies for its ability to mitigate oxidative stress and inflammation—key factors implicated in ALS progression. The FDA’s decision paves the way for Revive to accelerate its development programs with molecular hydrogen.
The National Center for Biotechnology Information article on Molecular hydrogen
https://pmc.ncbi.nlm.nih.gov/articles/PMC8861563/
Molecular hydrogen is a promising therapeutic agent for pulmonary disease
Zhiling FU 1, Jin ZHANG 1,✉
PMCID: PMC8861563 PMID: 35187885
Abstract
Molecular hydrogen exerts biological effects on nearly all organs. It has anti-oxidative, anti-inflammatory, and anti-aging effects and contributes to the regulation of autophagy and cell death. As the primary organ for gas exchange, the lungs are constantly exposed to various harmful environmental irritants. Short- or long-term exposure to these harmful substances often results in lung injury, causing respiratory and lung diseases. Acute and chronic respiratory diseases have high rates of morbidity and mortality and have become a major public health concern worldwide. For example, coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a global pandemic. An increasing number of studies have revealed that hydrogen may protect the lungs from diverse diseases, including acute lung injury, chronic obstructive pulmonary disease, asthma, lung cancer, pulmonary arterial hypertension, and pulmonary fibrosis. In this review, we highlight the multiple functions of hydrogen and the mechanisms underlying its protective effects in various lung diseases, with a focus on its roles in disease pathogenesis and clinical significance.
Is the DiagnaMed acquisition by Revive Therapeutics the reason for being contacted by a prominent clinical researcher from a U.S. University Cancer Institute? Is there really or could there be something there by using Bucillamine and Molecular Hydrogen to treat solid tumors?? Or is this smoke and mirrors designed to time?
https://www.globenewswire.com/news-release/2025/04/10/3059109/0/en/Revive-Therapeutics-to-Investigate-Bucillamine-s-Potential-in-Cancer-Treatment.html
Revive Therapeutics to Investigate Bucillamine’s Potential in Cancer Treatment
April 10, 2025 07:00 ET | Source: Revive Therapeutics Ltd.
TORONTO, April 10, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases, rare disorders, and medical countermeasures, announced today that it has been contacted by a prominent clinical researcher from a U.S. University Cancer Institute. The researcher aims to investigate Bucillamine’s potential as a cancer treatment, particularly for boosting anti-tumor effects in patients with advanced solid tumors. This evaluation of Bucillamine in solid tumors would be integrated into a broader study, supported by funding from the NIH and/or other government entities. This proposed research builds on our strategy of evaluating novel uses of Bucillamine in academic and government supporting studies, including the partnership with Defence R&D Canada – Suffield Research Centre, an agency of the Canadian Department of National Defence, evaluating Bucillamine as a potential treatment for nerve agent exposure. Results from this study are expected shortly.]
*****The share price at the time of this post. Could it one day go significantly higher......or significantly lower? We'll see.....******
hotmeat
2 weeks ago
I was speculating that the Canadian govt, through their version of the DOD, was funding RVV because there hasn't been any dilution for quite some time now.
Unless MF has secured, or set aside funds to carry out these Buccy trials I don't see where else the $$ could be coming from.
You haven't missed much in terms of progress....its basically been the usual vague Prs from the company that gives little to no details to get excited about.
I'm peruse the board periodically, like most I'm sure, patiently waiting for Mike to finally accomplish something tangible.
threebabiesbusy
1 month ago
https://www.biospace.com/press-releases/revive-therapeutics-advances-with-next-generation-bucillamine-development
Revive Therapeutics Advances with Next-Generation Bucillamine Development
June 4, 2025 | 4 min read
TORONTO, June 04, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to developing innovative therapeutics for critical medical needs, is pleased to announce the advancement of its next-generation lyophilized formulation of Bucillamine (“New Bucillamine”). Developed in collaboration with the esteemed University of Waterloo, this breakthrough aims to address significant unmet medical needs and unlock substantial value for shareholders.
Strategic Development Targeting High-Value Opportunities
Revive is strategically positioning New Bucillamine to target public health emergencies such as pandemic influenza and emerging infectious diseases. Additionally, the company will pursue FDA incentives, including Emergency Use Authorization, Orphan Drug Designation, Fast Track, and Breakthrough Therapy designations, maximizing the potential for rapid market entry and revenue generation.
Highlighting its potential, Bucillamine, a potent antioxidant and anti-inflammatory, already boasts FDA Orphan Drug Designation for ischemia-reperfusion injury following solid organ transplantation. This designation, awarded in 2022, underscores the compound's promise and provides a pathway to accelerated development and commercialization. Furthermore, research suggests Bucillamine may enhance solid tumor treatments in cancer and the Company has been contacted by a prominent clinical researcher from a U.S. University Cancer Institute to investigate Bucillamine for boosting anti-tumor effects in patients with advanced solid tumors, potentially opening up another significant market segment.
Strong Partnerships and Ongoing Research Driving Growth
Revive is committed to fostering strong pharmaceutical and government collaborations to accelerate New Bucillamine's clinical and commercial development. Currently, the company is working with Defence R&D Canada – Suffield Research Centre (DRDC), part of the Canadian Department of National Defence, on a study evaluating Bucillamine for nerve agent exposure. Positive results, expected by June 2025, could pave the way for human clinical trials in the second half of 2025 and subsequent FDA and Health Canada approvals. The potential applications of Bucillamine extend to traumatic brain injury and viral infections, further expanding its market potential and long-term value for investors.
Revive also reports that it is continuing to work with LTS Lohmann Therapie-System AG to settle the previously announced arbitration award.
About Revive Therapeutics Ltd.
Revive Therapeutics is a specialty life sciences company dedicated to developing innovative therapeutics for critical medical needs. Revive strategically prioritizes its drug development pipeline to leverage FDA regulatory incentives like Emergency Use Authorization, Orphan Drug, Fast Track, and Breakthrough Therapy designations, positioning for rapid advancement and market entry. Currently, our efforts are concentrated on unlocking the vast potential of Bucillamine for infectious diseases and medical countermeasures, including the pioneering treatment of nerve agent exposure. Furthermore, Revive is vigorously advancing our Psilocybin and molecular hydrogen therapeutic programs, exploring new frontiers in medical science. For more information, visit www.ReviveThera.com.
For more information, please contact:
Michael Frank
Chief Executive Officer
Revive Therapeutics Ltd.
Tel: 1 888 901 0036
Email: mfrank@revivethera.com
Website: www.revivethera.com
Neither the Canadian Securities Exchange nor its Regulation Services Provider has reviewed or accepts responsibility for the adequacy or accuracy of this release.
threebabiesbusy
1 month ago
Revive Therapeutics Advances Next-Gen Bucillamine for Critical Medical Needs
TipRanks Canadian Auto-Generated Newsdesk
Jun 04, 2025, 06:42 AM
Story Highlights
Revive Therapeutics is advancing its next-gen Bucillamine for public health emergencies.
Bucillamine’s potential spans cancer treatment, nerve agent exposure, and viral infections.
Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Revive Therapeutics Advances Next-Gen Bucillamine for Critical Medical Needs
Add TSE:RVV to your watchlist
and never miss an update about TSE:RVV stock!
Revive Therapeutics ( RVV +20.00% ? ) has issued an update.
Revive Therapeutics Ltd. has announced the advancement of its next-generation lyophilized formulation of Bucillamine, developed in collaboration with the University of Waterloo. This new formulation targets public health emergencies and aims to leverage FDA incentives for rapid market entry. Bucillamine already holds FDA Orphan Drug Designation for ischemia-reperfusion injury and has potential applications in cancer treatment, nerve agent exposure, traumatic brain injury, and viral infections. The company is working with Defence R&D Canada on a study for nerve agent exposure, with positive results potentially leading to human trials and regulatory approvals. These developments could significantly expand Bucillamine’s market potential and long-term value for investors.
Spark’s Take on TSE:RVV Stock
According to Spark, TipRanks’ AI Analyst, TSE:RVV is a Neutral.
The overall stock score for Revive Therapeutics is primarily influenced by significant financial challenges, such as no revenue and ongoing losses. Despite this, the company demonstrates short-term bullish technical indicators and has made strategic moves to expand its pipeline through recent acquisitions and collaborations. However, the negative P/E ratio and lack of profitability remain concerns.
To see Spark’s full report on TSE:RVV stock, click here.
More about Revive Therapeutics
Revive Therapeutics Ltd. is a specialty life sciences company focused on developing innovative therapeutics for critical medical needs. The company strategically prioritizes its drug development pipeline to leverage FDA regulatory incentives, aiming for rapid advancement and market entry. Revive’s efforts are concentrated on the potential of Bucillamine for infectious diseases and medical countermeasures, as well as advancing its Psilocybin and molecular hydrogen therapeutic programs.
Average Trading Volume: 257,272
Technical Sentiment Signal: Sell
Current Market Cap: C$12.56M
See more data about RVV stock on TipRanks’ Stock Analysis page.
Trending Articles:
Comcast Stock (NASDAQ:CMCSA) Gains With a New Sports Connection
“Lackluster” WWDC Ahead: Apple Stock (NASDAQ:AAPL) Gains as Strategy Questioned
“A Good Entry Point”; Tesla Stock (NASDAQ:TSLA) Jumps as Fundstrat Sees an Opportunity
Disclaimer & Disclosure
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue
Revive Therapeutics (TSE:RVV) Technical Sentiment
1 Day
3 Days
1 Week
2 Weeks
1 Month
Overall Consensus
Technical Analysis Consensus
Moving Averages Consensus
Unlock Full Indicators
Related Articles
Revive Therapeutics Advances Bucillamine Research for Nerve Agent Exposure
Revive Therapeutics Announces Shares for Debt Transaction to Preserve Cash
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Latest News Feed
Paramount Stock (NASDAQ:PARA) Notches Up Despite Internal Tragedy
56m ago
PARA
Deutsche Bank (DB) Considers Launching Its Own Stablecoin
57m ago
DB
Ford Stock (NYSE:F) Gains with Better Access to Rare Earths
1h ago
F
GM
U.S. Layoffs Surge despite Strong Jobs Data as Major Corporations Make Cuts
2h ago
threebabiesbusy
1 month ago
https://www.stocktitan.net/news/RVVTF/revive-therapeutics-advances-with-next-generation-bucillamine-hz634mnp5ipj.html
Revive Therapeutics (RVVTF) announces advancement in developing a next-generation lyophilized formulation of Bucillamine in collaboration with the University of Waterloo. The company is positioning New Bucillamine to target public health emergencies, including pandemic influenza and emerging infectious diseases. Bucillamine, which already holds FDA Orphan Drug Designation for ischemia-reperfusion injury in organ transplantation since 2022, shows promise in enhancing solid tumor treatments. The company is working with Defence R&D Canada to evaluate Bucillamine for nerve agent exposure, with results expected by June 2025. Clinical trials could begin in H2 2025, pending positive results. Revive is pursuing various FDA incentives and exploring partnerships to accelerate development and commercialization.
06/04/2025 - 05:55 AM
TORONTO, June 04, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to developing innovative therapeutics for critical medical needs, is pleased to announce the advancement of its next-generation lyophilized formulation of Bucillamine (“New Bucillamine”). Developed in collaboration with the esteemed University of Waterloo, this breakthrough aims to address significant unmet medical needs and unlock substantial value for shareholders.
Strategic Development Targeting High-Value Opportunities
Revive is strategically positioning New Bucillamine to target public health emergencies such as pandemic influenza and emerging infectious diseases. Additionally, the company will pursue FDA incentives, including Emergency Use Authorization, Orphan Drug Designation, Fast Track, and Breakthrough Therapy designations, maximizing the potential for rapid market entry and revenue generation.
Highlighting its potential, Bucillamine, a potent antioxidant and anti-inflammatory, already boasts FDA Orphan Drug Designation for ischemia-reperfusion injury following solid organ transplantation. This designation, awarded in 2022, underscores the compound's promise and provides a pathway to accelerated development and commercialization. Furthermore, research suggests Bucillamine may enhance solid tumor treatments in cancer and the Company has been contacted by a prominent clinical researcher from a U.S. University Cancer Institute to investigate Bucillamine for boosting anti-tumor effects in patients with advanced solid tumors, potentially opening up another significant market segment.
Positive
FDA Orphan Drug Designation already secured for ischemia-reperfusion injury application
Potential expansion into multiple high-value markets including cancer treatment and nerve agent exposure
Ongoing collaboration with Defence R&D Canada with results expected June 2025
Strategic pursuit of multiple FDA incentives including Emergency Use Authorization and Fast Track designation
Negative
Pending arbitration settlement with LTS Lohmann Therapie-System AG
Clinical trials for nerve agent exposure application not yet started
No immediate revenue generation from current developments
GLTA!
3BB
Classic Warrior
3 months ago
One can only hope this goes up as quickly as it went down. We haven't seen any good trial news in years, just lots of letters of intent, etc. Hopefully, the trial news come out at some point, backing the relevance and anti-inflammatory nature of Bucy, $.15 with good news and support from Canada doesn't seem out of the question. .
News
Market Data
Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
Ask ADVFN Intelligence (AI)
ReikoBlack
2 weeks ago
Gatorca
1 month ago
Ecomike
2 months ago
